17.2 Status Epilepticus & Non-Convulsive Status Epilepticus

Operational Definitions and Receptor Neurobiology

In 2015, the International League Against Epilepsy (ILAE) established a revised, mechanistic definition of status epilepticus based on a two-dimensional framework: the first dimension represents the time threshold beyond which an ongoing seizure is abnormally prolonged and unlikely to terminate spontaneously ($t_1$), and the second dimension represents the time point beyond which continuous seizure activity produces long-term, irreversible neuronal necrosis and network alteration ($t_2$).

For Generalized Convulsive Status Epilepticus (GCSE), these operational time points are defined as:

• Time Point 1 ($t_1 = 5\text{ minutes}$): Normal generalized convulsive seizures terminate spontaneously within 1 to 2 minutes. A convulsive seizure persisting beyond 5 minutes satisfies the operational definition of status epilepticus and mandates the immediate initiation of Phase 1 emergent antiepileptic pharmacotherapy.
• Time Point 2 ($t_2 = 30\text{ minutes}$): Continuous convulsive seizure activity lasting beyond 30 minutes produces severe, irreversible neuronal cell death (predominantly in the CA1 and CA3 regions of the hippocampus and laminar neocortex) and severe systemic decompensation.

For Non-Convulsive Status Epilepticus (NCSE), the operational thresholds are longer: $t_1 = 10\text{ minutes}$ and $t_2 = 60\text{ minutes}$.

Molecular Receptor Trafficking and Pharmacoresistance

The rapid transition of self-terminating seizures into refractory status epilepticus is driven by altered trafficking of postsynaptic neurotransmitter receptors:

1. $\text{GABA}_A$ Receptor Internalization: During sustained seizure activity, continuous chloride influx triggers clathrin-dependent endocytosis and internalization of synaptic $\text{GABA}_A$ receptors into the intracellular cytoplasm, where they undergo dephosphorylation and lysosomal degradation. Consequently, synaptic inhibitory GABAergic transmission declines exponentially within minutes, rendering the patient rapidly refractory to first-line benzodiazepine therapy.
2. NMDA/AMPA Receptor Upregulation: Concurrently, intracellular vesicles containing excitatory glutamate receptors (predominantly $\text{NMDA}$ and $\text{AMPA}$ subtypes) translocate to and incorporate into the postsynaptic membrane. Excessive glutamate release drives continuous, unconstrained intracellular calcium influx, triggering mitochondrial dysfunction, free radical generation, caspase activation, and excitotoxic neuronal necrosis.

Systemic Pathophysiology: Phase 1 vs. Phase 2

• Phase 1 Compensation ($0-30\text{ minutes}$): Intense autonomic sympathetic discharge produces severe tachycardia, hypertension, hyperglycemia, hyperthermia, and massive lactic acidosis. Cerebral blood flow is markedly augmented to meet massive cerebral metabolic oxygen demands ($CMRO_2$).
• Phase 2 Decompensation ($>30\text{ minutes}$): Autonomic exhaustion and systemic collapse ensue. Patients develop systemic hypotension, uncoupling of cerebral blood flow from metabolic demand, hyperpyrexia ($>40^\circ\text{C}$), severe mixed metabolic and respiratory acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, disseminated intravascular coagulation (DIC), and cardiac dysrhythmias.

---

Three-Phase Tiered Treatment Algorithm

Successful management of status epilepticus requires a rigid, time-sensitive, three-phase escalation protocol designed to terminate both clinical convulsions and occult electrographic seizures before irreversible injury occurs.

Phase 1: Emergent Initial Therapy ($0 - 5\text{ Minutes}$)

Benzodiazepines are the uncontested first-line therapy. The choice of agent depends entirely on whether secure intravenous (IV) access is established:

• Intravenous Access Present: IV Lorazepam is preferred due to its lower lipophilicity compared to diazepam, resulting in prolonged central nervous system retention and a longer effective anticonvulsant duration (4 to 14 hours). The guideline dose is $0.1\text{ mg/kg}$ IV push (typically $4\text{ mg}$ bolus infused at $2\text{ mg/min}$), which may be repeated once at 5 to 10 minutes if seizures persist.
• Intravenous Access Absent: Intramuscular (IM) Midazolam is the first-line standard. The landmark RAMPART trial (Rapid Anticonvulsant Medication Prior to Arrival Trial, NEJM 2012) demonstrated that IM midazolam administered via an autoinjector ($10\text{ mg}$ IM for adults $>40\text{ kg}$; $5\text{ mg}$ IM for $13-40\text{ kg}$) is non-inferior—and in clinical practice superior—to IV lorazepam in pre-hospital status epilepticus because it eliminates the critical time delays required to establish peripheral venous access.
• Alternative Routes: Rectal diazepam ($0.2\text{ mg/kg}$, max $20\text{ mg}$) or intranasal midazolam ($0.2\text{ mg/kg}$, max $10\text{ mg}$) if IM midazolam cannot be administered.

Phase 2: Urgent Control Therapy ($5 - 20\text{ Minutes}$)

If seizures persist despite adequate initial benzodiazepine dosing, clinicians must immediately initiate a second-line, non-sedating intravenous antiseizure medication (ASM). In addition, if a benzodiazepine successfully terminates the seizure, an urgent Phase 2 agent should still be administered to maintain seizure control and prevent recurrence.

The ESETT Trial Synthesis (NEJM 2019)

The Established Status Epilepticus Treatment Trial (ESETT) was a multicenter, randomized, double-blind, comparative-effectiveness trial evaluating 384 children and adults with benzodiazepine-refractory convulsive status epilepticus. Patients were randomized to receive one of three non-sedating IV antiseizure regimens:

1. Levetiracetam: $60\text{ mg/kg}$ IV (maximum $4500\text{ mg}$) infused over 10 minutes.
2. Fosphenytoin: $20\text{ mg PE/kg}$ IV (maximum $1500\text{ mg PE}$) infused at up to $150\text{ mg PE/min}$.
3. Sodium Valproate: $40\text{ mg/kg}$ IV (maximum $3000\text{ mg}$) infused over 10 minutes.

Key Findings:

• Therapeutic Equivalence: The primary outcome—cessation of status epilepticus and improvement in responsiveness at 60 minutes without rescue therapy—occurred in approximately 47% of patients in the levetiracetam group, 45% in the fosphenytoin group, and 46% in the valproate group. There were no statistically significant differences in efficacy.
• Safety Equivalence: Rates of life-threatening hypotension and respiratory depression were equally low (~1% to 3%) across all three arms.
• Clinical Selection Considerations:
  • Levetiracetam: Highly favored for broad availability, rapid 10-minute infusion, absence of hepatic metabolism (cleared renally), and lack of significant cytochrome P450 drug-drug interactions. Avoid in patients with acute psychotic agitation.
  • Fosphenytoin: Water-soluble prodrug of phenytoin dosed in Phenytoin Equivalents (PE). Unlike phenytoin, it lacks the propylene glycol vehicle, so infusion-site injury and "purple glove syndrome" are much less likely; hypotension and arrhythmias still occur, so cardiac and blood pressure monitoring are required. It can be infused at up to $150\text{ mg PE/min}$ (three times faster than phenytoin). Contraindicated in sinus bradycardia, sinoatrial block, and second- or third-degree AV block.
  • Sodium Valproate: Highly effective broad-spectrum agent with minimal cardiovascular toxicity. Strictly contraindicated in patients with acute liver failure, pancreatitis, urea cycle disorders, pregnancy, and known or suspected mitochondrial disorders (specifically POLG mutations, where valproate precipitates fulminant, fatal hepatic necrosis).

Phase 3: Refractory Status Epilepticus (RSE, $>20 - 40\text{ Minutes}$)

Refractory Status Epilepticus (RSE) is defined as status epilepticus that continues clinically or electrographically despite adequate doses of an initial first-line benzodiazepine and a second-line non-sedating intravenous ASM. Approximately 30% to 40% of status epilepticus cases progress to RSE.

Management of Phase 3 mandates immediate escalation:

1. Airway Protection: Perform endotracheal intubation with rapid-sequence induction.
2. Invasive Hemodynamics: Place an indwelling arterial catheter for continuous arterial pressure monitoring, as continuous anesthetic infusions cause significant vasodilation and myocardial depression.
3. Continuous IV Anesthetic Infusions:
   • Propofol: Bolus $1-2\text{ mg/kg}$ over 5 minutes, followed by continuous infusion at $2-10\text{ mg/kg/h}$ ($30-150\ \mu\text{g/kg/min}$). Acts via $\text{GABA}_A$ receptor potentiation and NMDA inhibition. Rapid onset and clearance permit rapid neurological wake-up tests.
   • Midazolam: Bolus $0.2\text{ mg/kg}$, followed by continuous infusion at $0.05-2\text{ mg/kg/h}$. Rapidly effective, but highly lipophilic; prolonged infusions lead to peripheral tissue saturation, significant accumulation, and tachyphylaxis.
   • Ketamine: Non-competitive NMDA receptor antagonist. Bolus $1-2\text{ mg/kg}$, followed by continuous infusion at $1-5\text{ mg/kg/h}$. Highly advantageous in hemodynamically marginal patients because it stimulates sympathetic tone, and mechanistically targets the upregulated NMDA receptors of prolonged status epilepticus.
   • Pentobarbital / Thiopental: High-potency barbiturates. Bolus $5\text{ mg/kg}$, followed by continuous infusion at $1-5\text{ mg/kg/h}$. Reserved for severe RSE refractory to propofol/midazolam. Causes profound vasoplegia, myocardial depression requiring high-dose vasopressors, paralytic ileus, infection risk, and prolonged clearance (half-life $>30-60\text{ hours}$).

Continuous EEG (cEEG) Target and Duration

Continuous EEG monitoring is mandatory during Phase 3. The therapeutic target of continuous anesthetic titration is either complete electrographic seizure cessation or burst suppression (typically targeting an inter-burst interval of 8 to 15 seconds, or a suppression ratio of 80% to 90%).

Once burst suppression is achieved, the anesthetic infusion is maintained for 24 to 48 hours, during which background non-sedating antiepileptic medications are optimized. The continuous anesthetic is then slowly weaned over 12 to 24 hours under continuous EEG observation to detect seizure recrudescence.

Propofol Infusion Syndrome (PRIS)

PRIS is a lethal toxicological complication of propofol that impairs cellular mitochondrial fatty acid oxidation and oxidative phosphorylation. It classically develops when propofol is infused at doses $>4-5\text{ mg/kg/h}$ ($>67-83\ \mu\text{g/kg/min}$) for $>48\text{ hours}$.

• Clinical Manifestations: Severe refractory metabolic acidosis, marked hyperlactatemia, rhabdomyolysis (massive creatine kinase elevation, hyperkalemia, acute kidney injury), hepatomegaly, hypertriglyceridemia, and cardiovascular collapse marked by refractory bradycardia, widened QRS, and Brugada-like ST elevations in $V_1-V_3$.
• Management: Immediate cessation of propofol infusion, transition to an alternative continuous anesthetic (midazolam or ketamine), aggressive supportive hemodynamic management, and early hemodialysis or continuous renal replacement therapy for metabolic acidosis and hyperkalemia.

---

Non-Convulsive Status Epilepticus (NCSE) and Continuous EEG

Non-Convulsive Status Epilepticus (NCSE) represents electrographic status epilepticus in the absence of generalized tonic-clonic convulsions. It is exceedingly common in the critical care unit: continuous EEG studies find nonconvulsive seizures or NCSE in roughly 10% to 20% of comatose ICU patients without overt motor activity (higher in some cohorts) following cardiac arrest, severe traumatic brain injury, acute intracerebral hemorrhage, or treated convulsive status epilepticus.

Clinical Presentation and Salzburg Criteria

NCSE presents subtly as unexplained coma, prolonged stupor, fluctuating delirium, abulia, wandering gaze, or discrete micro-movements (subtle perioral twitching, eyelid fluttering, nystagmoid jerking). Accurate diagnosis requires continuous video-EEG (cEEG) evaluated using the 2015 Salzburg Criteria.

In patients without pre-existing epileptic encephalopathy, NCSE is diagnosed if cEEG demonstrates:

1. Epileptiform discharges $>2.5\text{ Hz}$; OR
2. Epileptiform discharges $\le 2.5\text{ Hz}$ OR rhythmic delta/theta activity ($>0.5\text{ Hz}$) PLUS at least one of the following secondary criteria:
   • Evolution in frequency ($>1\text{ Hz}$ shift), morphology, or spatial distribution over time.
   • Subtle clinical ictal phenomena occurring concurrently with the EEG discharges.
   • Rapid clinical and electrographic resolution following an intravenous test dose of a fast-acting, non-sedating antiepileptic drug (e.g., IV levetiracetam, lacosamide, or small-dose lorazepam $1\text{ mg}$).

Indications for Continuous Video-EEG in the ICU

• Persistent coma or failure to regain baseline consciousness within 30 to 60 minutes following termination of convulsive status epilepticus.
• Unexplained fluctuating altered mental status or acute neurological deterioration in patients with severe acute brain injury (ICH, SAH, TBI, stroke).
• Post-cardiac arrest comatose patients undergoing targeted temperature management (TTM).
• Paroxysmal unexplained movements, repetitive gaze deviation, or unexplained autonomic instability (sudden tachycardia, hypertension, pupillary dilation).